Proteome analysis of human substantia nigra in Parkinson's disease.
about
Proteome analysis of human substantia nigra in Parkinson's diseaseQuantitative proteomic analysis of human substantia nigra in Alzheimer's disease, Huntington's disease and Multiple sclerosisThioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signalingSpecific changes of serum proteins in Parkinson's disease patientsA Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma CellsRoles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease.Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration.Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobuleCrystallization and preliminary crystallographic analysis of mouse peroxiredoxin II with significant pseudosymmetry.Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse modelNeuroproteomics as a promising tool in Parkinson's disease research.Neuroproteomics approaches to decipher neuronal regeneration and degeneration.Biomarkers for cognitive impairment in Parkinson disease.Gene expression profiling and association with prion-related lesions in the medulla oblongata of symptomatic natural scrapie animals.Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanismsBiomarker discovery in neurodegenerative diseases: a proteomic approach.Tensor-based morphometry and stereology reveal brain pathology in the complexin1 knockout mouseCerebrospinal fluid biomarkers for dementia with lewy bodies.Repeated intratracheal instillation of PM10 induces lipid reshaping in lung parenchyma and in extra-pulmonary tissuesRegion specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells.Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cellsKorean Red Ginseng inhibits apoptosis in neuroblastoma cells via estrogen receptor β-mediated phosphatidylinositol-3 kinase/Akt signaling.Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigraPeroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeysNeuroGeM, a knowledgebase of genetic modifiers in neurodegenerative diseasesBridging molecular genetics and biomarkers in lewy body and related disordersProteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative diseaseComplexin2 modulates working memory-related neural activity in patients with schizophrenia.Dynamics of subcellular proteomes during brain developmentComparative mitochondrial proteomics: perspective in human diseases.The use of MALDI-MSI in the investigation of psychiatric and neurodegenerative disorders: A review.Peroxiredoxin-2 up-regulation in inflammatory bowel disease: Friend or foe?How proteomics reveals potential biomarkers in brain diseases.2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases.Translational research in central nervous system drug discovery.
P2860
Q21245637-3A14727F-C4D0-4226-AF34-615F1432A450Q24297593-E20EB8A9-C7C7-41C6-B79C-DDDA51DF104AQ28389739-59EE16E7-0EDE-4FB6-BAA3-DDC21A908B79Q28538260-C8305210-348E-4FDF-AD96-7965693A0C21Q28551285-1FE274F3-2F24-4049-9B5A-64907BE0CC2AQ30394816-9F20AE6D-6638-49ED-B946-A45E44FEC2FCQ30446460-A60C1DD0-49CE-4A36-8E5A-370769D53703Q30659873-6193A26F-8262-4EC4-9583-7998C44D3E98Q33643522-6886DA98-A2B9-484B-A7E1-5FC67AE3196CQ33707363-483261D2-42CA-43C5-9ACB-141A2D767134Q33746261-B15EF207-0C66-4593-85F1-0815C9F87CB2Q33810589-F08255FA-B25D-4434-A711-61AA7A0BC2D1Q33821316-E0363B00-829D-4DE3-A64B-36E93FB54A35Q33855014-64CC02D6-5805-4EBD-A566-210E3455AAC3Q33896664-FA8DDF47-A05A-41F6-B75F-05969A3B9884Q33918266-1B78D7CD-3149-44BB-9C7E-0174162DBC67Q34032608-350DB570-BA83-400F-9C6E-23B649F677E7Q34109658-9CC5E131-94B7-475E-8FDE-B974AEE0B8BBQ34125681-ABA8688C-AF69-46A3-8E50-DED97415577AQ34185958-BEB0FCE7-2596-4FDB-A352-5DB0AF858B70Q34248241-ACD94DCE-369E-4B78-8008-3A8BE15411D1Q34257997-F34105C2-41E8-4CDF-8544-2F455A520172Q34380871-C27858C2-8D63-4344-ADE6-FF9C24756008Q34447581-0125EDF0-A13B-43E5-9A31-60584A5DCFA6Q34505750-669AAB98-F3E6-4C6B-84BF-ADA2C084FFFFQ34719317-3025043F-124F-4A2D-9EA7-51ED6586FD3EQ34768987-A44158C6-9E71-40C9-941F-B425751EB858Q34806527-0053A1D1-C53A-403B-8904-E149D414043FQ34990005-975A24E3-1C32-4980-B780-A53BF3C3D725Q35042712-4802E878-A14C-4668-9FA4-102F4B69F80BQ35094391-83754A1B-FC94-473A-BB78-889D2203E190Q35125001-48105362-90CF-4B0F-8190-9680509FAE6AQ35126062-A53EC25F-539A-4F28-AEB0-F4442128F730Q35906775-41857057-4E98-40BC-99C0-ADCB1B4EBD51Q35914386-1A20F665-9F0F-4A33-A227-E2CEC592AC8AQ36052708-BF368331-C346-4BC9-A9E2-EF00C1E37F43Q36199233-4D4D1AAD-2FFB-444A-A368-2089E9221939Q36322155-3BF769E7-0E14-4FE5-B3CF-A438FB80E820Q36381232-AB58AA6A-2F17-47E6-B3D8-3B45372F81D6Q36401418-89316144-E633-4877-9247-878096369A9A
P2860
Proteome analysis of human substantia nigra in Parkinson's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Proteome analysis of human substantia nigra in Parkinson's disease.
@ast
Proteome analysis of human substantia nigra in Parkinson's disease.
@en
type
label
Proteome analysis of human substantia nigra in Parkinson's disease.
@ast
Proteome analysis of human substantia nigra in Parkinson's disease.
@en
prefLabel
Proteome analysis of human substantia nigra in Parkinson's disease.
@ast
Proteome analysis of human substantia nigra in Parkinson's disease.
@en
P2093
P356
P1433
P1476
Proteome analysis of human substantia nigra in Parkinson's disease
@en
P2093
Bruno Bergamasco
Davide Corpillo
Leonardo Lopiano
Sabrina Giraudo
P304
P356
10.1002/PMIC.200400848
P577
2004-12-01T00:00:00Z